申请人:Turning Point Therapeutics, Inc.
公开号:EP3733187A1
公开(公告)日:2020-11-04
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
本公开涉及某些二芳基大环化合物,特别是(7S,13R)-11-氟-7,13-二甲基-6,7,13,14-四氢-1,15-苯并吡唑并[4,3-f][1,4,8,10]苯并氧杂三氮杂环十三烷-4(5H)-酮在治疗哺乳动物疾病中的用途。本公开还涉及包括此类化合物的组合物,以及使用此类组合物治疗哺乳动物,尤其是人类疾病的方法。